Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and ...

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced ...

How do you find the right stocks to buy? It’s a simple question, but the answer can be challenging. Thankfully, there are ...

Gait changes. Fallen arches. A whole new shoe size. Many women experience these transformations during pregnancy, but the phenomenon is rarely discussed outside the mom group text.

In a report released on November 8, David Risinger from Leerink Partners maintained a Buy rating on Tectonic Therapeutic (TECX – Research ...

Tectonic announced topline results from the study on September 19, 2024. About TX45, a long-acting Fc-relaxin fusion protein Tectonic’s lead program, TX45, is an Fc-relaxin fusion protein with ...

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early ...

Generally, the pelvis maintains a high level of stability as you run or simply move throughout the day. However, once you become pregnant, a little hormone known as relaxin makes a dramatic entrance.

Tectonic announced topline results from the study on September 19, 2024. Tectonic’s lead program, TX45, is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties ...

TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic ...

G protein–coupled receptors (GPCRs) are one of the most popular target classes investigated in the drug-discovery process. With its selection of kits (cAMP femto, cAMP dynamic and cAMP HiRange ...

But there’s one crucial aspect often overlooked: choosing the perfect name for your new woolly warrior. As Shakespeare once ...